Mifepristone: where do we come from and where are we going?
This review discusses the historical development, current applications, and future research directions for mifepristone, a medication used primarily for medical abortion and Cushing's syndrome.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (100)
- Daily Low-Dose Mifepristone Has Contraceptive Potential by Suppressing Ovulation and Menstruation: A Double-Blind Randomized Control Trial of 2 and 5 mg per Day for 120 Days via openalex
- Effect of long-term treatment with low-dose mifepristone on the endometrium via openalex
- Effects of long-term low-dose mifepristone on reproductive function in women via openalex
- Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis via openalex
- Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator via openalex
- Progesterone receptor antagonists and selective progesterone receptor modulators: proven and potential clinical applications via openalex
- Progesterone receptor modulators and the endometrium: changes and consequences† via openalex
- Progesterone Receptor Modulators in Endometriosis: A New Therapeutic Option via openalex
- W1910306760 via openalex
- W1928861982 via openalex
- W1965768287 via openalex
- W1966734750 via openalex
- W1969823407 via openalex
- W1974377866 via openalex
- W1975486822 via openalex
- W1976158428 via openalex
- W1976368322 via openalex
- W1978311718 via openalex
- W1978845466 via openalex
- W1982223898 via openalex
- W1984592479 via openalex
- W1984901643 via openalex
- W1992344390 via openalex
- W1995082078 via openalex
- W1996417658 via openalex
- W2002239473 via openalex
- W2002518740 via openalex
- W2004829167 via openalex
- W2005256844 via openalex
- W2007048730 via openalex
- W2010733380 via openalex
- W2013068772 via openalex
- W2015929001 via openalex
- W2016699471 via openalex
- W2018274205 via openalex
- W2019745575 via openalex
- W2022867038 via openalex
- W2023946729 via openalex
- W2026392453 via openalex
- W2026752384 via openalex
- W2027588860 via openalex
- W2030567114 via openalex
- W2032237183 via openalex
- W2032289170 via openalex
- W2035362535 via openalex
- W2035366757 via openalex
- W2039633328 via openalex
- W2039871782 via openalex
- W2040929385 via openalex
- W2041145382 via openalex
- W2043813600 via openalex
- W2045524208 via openalex
- W2046141468 via openalex
- W2047347660 via openalex
- W2047372977 via openalex
- W2048954135 via openalex
- W2048957217 via openalex
- W2053628474 via openalex
- W2056447394 via openalex
- W2059587221 via openalex
- W2060010595 via openalex
- W2063169494 via openalex
- W2066564642 via openalex
- W2067176980 via openalex
- W2072652930 via openalex
- W2077479660 via openalex
- W2078370543 via openalex
- W2079241337 via openalex
- W2080639359 via openalex
- W2082368668 via openalex
- W2084815884 via openalex
- W2093512443 via openalex
- W2095976035 via openalex
- W2096483577 via openalex
- W2099389398 via openalex
- W2101356852 via openalex
- W2102218899 via openalex
- W2108010472 via openalex
- W2109942881 via openalex
- W2111008791 via openalex
- W2112637703 via openalex
- W2114428420 via openalex
- W2122146138 via openalex
- W2122588145 via openalex
- W2122896665 via openalex
- W2124484554 via openalex
- W2127085373 via openalex
- W2127126426 via openalex
- W2130196753 via openalex
- W2134535954 via openalex
- W2136657922 via openalex
- W2138086034 via openalex
- W2139620826 via openalex
- W2139973581 via openalex
- W2142662718 via openalex
- W2147836164 via openalex
- W2150321179 via openalex
- W2151274670 via openalex
- W2153497318 via openalex
- W2154880208 via openalex
Cited by (12)
- Clinical Utility of Mifepristone: Apprising the Expanding Horizons 2022
- Mifepristone Treats Symptomatic Adenomyosis: A Multicentre, Randomized, Double-Blind and Placebo-Controlled Trial 2021
- Investigational drugs for the treatment of endometriosis, an update on recent developments 2018
- Selektive Progesteronrezeptormodulatoren 2016
- Innovations in classical hormonal targets for endometriosis 2015
- An overview of early drug development for endometriosis 2015
- How does Endometriosis affect Women\'s Life, focusing on Endometriomas? 2014
- Mifepristone: a potential clinical agent based on its anti-progesterone and anti-glucocorticoid properties 2013
- Report on Repeated Mifepristone Treatment for Uterine Fibroids or Endometriosis 2013
- The immninent dawn of SPRMs in obstetrics and gynecology 2012
- New trends for the medical treatment of endometriosis 2012
- Tratamiento de la endometriosis con 5mg o 25mg diarios de mifepristona durante 6 meses. Ensayo clínico aleatorizado, doble ciego 2011
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:17:00.782903+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00